These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 12971034)
1. Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. Smith JA; Newman RA; Hausheer FH; Madden T J Clin Pharmacol; 2003 Sep; 43(9):1008-14. PubMed ID: 12971034 [TBL] [Abstract][Full Text] [Related]
2. Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein. Yao S; Petluru P; Parker A; Ding D; Chen X; Huang Q; Kochat H; Hausheer F Cancer Chemother Pharmacol; 2015 Apr; 75(4):719-28. PubMed ID: 25634596 [TBL] [Abstract][Full Text] [Related]
3. Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine. Smith JA; Hausheer F; Newman RA; Madden TL J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):117-24. PubMed ID: 11499615 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of liposomal curcumin cytochrome p450 metabolism. Mach CM; Chen JH; Mosley SA; Kurzrock R; Smith JA Anticancer Res; 2010 Mar; 30(3):811-4. PubMed ID: 20393001 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. Mach CM; Fugii H; Wakame K; Smith J J Soc Integr Oncol; 2008; 6(3):105-9. PubMed ID: 19087767 [TBL] [Abstract][Full Text] [Related]
6. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs. Morse DS; Abernethy DR; Greenblatt DJ Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087 [TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG; Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560 [TBL] [Abstract][Full Text] [Related]
8. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Finlay GJ; Baguley BC Cancer Chemother Pharmacol; 2000; 45(5):417-22. PubMed ID: 10803926 [TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Munster PN; Daud AI Expert Opin Investig Drugs; 2011 Nov; 20(11):1565-74. PubMed ID: 21985236 [TBL] [Abstract][Full Text] [Related]
10. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. Vanstraelen K; Wauters J; De Loor H; Vercammen I; Annaert P; Lagrou K; Spriet I J Pharm Sci; 2014 Aug; 103(8):2565-70. PubMed ID: 24961809 [TBL] [Abstract][Full Text] [Related]
11. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Brandes LJ; Queen GM; LaBella FS Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318 [TBL] [Abstract][Full Text] [Related]
12. Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. MacKichan JJ; Zola EM Br J Clin Pharmacol; 1984 Oct; 18(4):487-93. PubMed ID: 6487490 [TBL] [Abstract][Full Text] [Related]
13. Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. Motoya T; Thevanayagam LN; Blaschke TF; Au S; Stone JA; Jayewardene AL; Chi J; Aweeka FT HIV Med; 2006 Mar; 7(2):122-8. PubMed ID: 16420257 [TBL] [Abstract][Full Text] [Related]
14. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Bailey DN; Briggs JR Ther Drug Monit; 2004 Feb; 26(1):40-3. PubMed ID: 14749548 [TBL] [Abstract][Full Text] [Related]
15. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Jacob E; Scorsone K; Blaney SM; D'Argenio DZ; Berg SL Pediatr Blood Cancer; 2008 Apr; 50(4):757-60. PubMed ID: 17849472 [TBL] [Abstract][Full Text] [Related]
16. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032 [TBL] [Abstract][Full Text] [Related]
17. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. Wanwimolruk S; Denton JR J Pharm Pharmacol; 1992 Oct; 44(10):806-11. PubMed ID: 1360505 [TBL] [Abstract][Full Text] [Related]
18. Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and α-1 acid glycoprotein. Bista SR; Haywood A; Hardy J; Lobb M; Tapuni A; Norris R Xenobiotica; 2015 Mar; 45(3):207-12. PubMed ID: 25314012 [TBL] [Abstract][Full Text] [Related]
19. [Drug interactions with antiepileptic agents]. Turnheim K Wien Klin Wochenschr; 2004 Feb; 116(4):112-8. PubMed ID: 15038401 [TBL] [Abstract][Full Text] [Related]
20. Plasma protein binding of drugs after severe burn injury. Martyn JA; Abernethy DR; Greenblatt DJ Clin Pharmacol Ther; 1984 Apr; 35(4):535-9. PubMed ID: 6705453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]